AZT — Arcticzymes Technologies ASA Share News
0.000.00%
Last trade - 00:00- NOK1.02bn
- NOK776.49m
- NOK112.62m
Brief: Biotec Pharmacon's Unit Granted EUR 254,000 Funding
Brief: Biotec Pharmacon Awarded Grant From Research Council Of Norway
Brief: Biotec Pharmacon EBITDA Loss Narrows To NOK 1.6 Million
Brief: Biotec Pharmacon Says Woulgan Results Expected In Late Q2
Brief: Biotec Pharmacon Unit And Vectron Biosolutions Sign License Agreement
Brief: ArcticZymes Signs Supply Agreement In Japan
Brief: Biotec Renews Clinical Trial Deal With Memorial Sloan Kettering Cancer Center
Brief: Biotec Pharmacon Q3 EBITDA Loss Narrows To NOK 0.2 Mln
Brief: Biotec Pharmacon Says ArcticZymes AS secures first supply agreement for utility of Salt Active Nuclease in Gene Therapy
Brief: Biotec Pharmacon Changes Management In The Wound Care Area
Brief: Biotec Pharmacon Q2 EBITDA Loss Narrows To NOK 4.2 Mln
Brief: Biotec Pharmacon: Arcticzymes Launches Its First Proteinase Enzyme
Brief: Biotec Raises NOK 23 Mln From Private Placement
Brief: Biotec Offers Up To 4.4 Mln New Shares In Private Placement
Brief: Biotec Pharmacon Says Results From Neuroblastoma Phase II Vaccine Study Indicate Promising Adjuvant (SBG) Effect
Brief: Biotec Pharmacon Unit Signs Agreement With Ohly GmbH
Biotec Pharmacon: Wounds heal, shares rise
Brief: Biotec Pharmacon: Erik Thorsen To Leave His Position As Chairman
Brief: Biotec Pharmacon Q4 EBITDA Loss Narrows To NOK 7.2 Million